StockBeat: Galapagos' Halo Slips
- ByInvesting.com-
By Geoffrey Smith Investing.com -- Onno van de Stolpe named his biotech startup after a chain of islands famed for the diversity and inventiveness of its wildlife. It’s ironic,...
By Geoffrey Smith Investing.com -- Onno van de Stolpe named his biotech startup after a chain of islands famed for the diversity and inventiveness of its wildlife. It’s ironic,...
By Sruthi Shankar (Reuters) - European stocks closed higher on Wednesday following new record highs for Wall Street's main indexes, while UK airlines rallied on hopes of a shorter...
(Reuters) - Shares of Gilead Sciences (O:GILD) fell 3% after the U.S. Food and Drug Administration declined to approve its experimental rheumatoid arthritis treatment, a major...
Galapagos NV (NASDAQ:GLPG) announced that the FDA has granted Fast Track designation to its pipeline candidate GLPG1972/S201086 for the treatment of osteoarthritis (OA)....
Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive...
Investors are always looking for stocks that are poised to beat at earnings season and Galapagos NV (NASDAQ:GLPG) may be one such company. The firm has earnings coming up pretty...
Galapagos NV is a Belgium-based clinical-stage biotechnology company. The Company is focused on the discovery and development of small molecule medicines with novel modes of action. Its pipeline comprises Phase 3, 2, 1, pre-clinical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. The Company aims to develop a portfolio of clinical-stage therapies for the enhancement of existing treatment paradigms. In addition, the Company’s mission is to develop a number of medicines based on the discovery of novel targets. Galapagos NV also discovers which proteins that are involved in causing diseases such as, rheumatoid, arthritis, inflammatory bowel disease and fibrosis. Galapagos aims to develop small molecules that inhibit these targets, restore the balance and thereby positively influence the course of the disease.
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Buy |
| Technical Indicators | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Neutral |
| Summary | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Neutral |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 169.76 | 170.96 | 169.39 | -0.94 | -0.55% | 2.25M | NASDAQ | |||
| 53.26 | 53.47 | 52.79 | +0.51 | +0.97% | 8.25M | NYSE | |||
| 79.37 | 79.41 | 76.90 | +4.02 | +5.34% | 59.18M | NASDAQ | |||
| 123.47 | 124.99 | 120.57 | +4.35 | +3.65% | 18.12M | NYSE | |||
| 178.40 | 179.12 | 177.51 | +0.10 | +0.06% | 2.38M | NYSE | |||
| 45.24 | 46.35 | 44.95 | +0.01 | 0.00% | 1.22M | NYSE | |||
| 7.14 | 7.34 | 6.92 | +0.29 | +4.23% | 4.43M | NYSE | |||
| 0.1239 | 0.13 | 0.122 | -0.0031 | -2.44% | 1.11M | NYSE | |||
| 1.04 | 1.04 | 0.95 | +0.1000 | +10.64% | 5.17M | NYSE | |||
| 33.41 | 33.92 | 33.27 | +0.88 | +2.69% | 6.31M | NYSE | |||
| 12.87 | 12.95 | 12.63 | +0.33 | +2.63% | 699.48K | NYSE | |||
| 4.44 | 4.47 | 4.44 | 0.000 | 0.00% | 0.00 | NYSE | |||
| 51.88 | 52.34 | 50.24 | +1.36 | +2.69% | 242.73K | NASDAQ | |||
| 7.55 | 7.57 | 7.47 | +0.14 | +1.82% | 2.91M | NASDAQ | |||
| 43.20 | 43.55 | 40.92 | +4.06 | +10.37% | 3.33M | NYSE |